ResMed (RMD) Reports In-Line Q1 EPS, Beats on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $222.51 -2.56%
EPS Growth %: +5.5%
Financial Fact:
Other, net (note 12): 1.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Other, net (note 12): 1.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q1 EPS of $0.66, in-line with the analyst estimate of $0.66. Revenue for the quarter came in at $523.7 million versus the consensus estimate of $505.61 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- GE Aerospace to acquire Consolidated Precision in $11.75b deal
- UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
